Published August 5, 2024
Danaher & the Bioprocessing FDA Approval Process
inpractise.com/articles/danaher-and-the-bioprocessing-fda-approval-process
Executive Bio
Former Head of Sales, GE Life Sciences
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
But in terms of the customer, let's say, at the drug discovery phase, are they focusing more on the resins or the media, or are both equally critical?
Equally. Yes, and that's why you have upstream R&D, upstream process development, and similar functions. You run downstream processes in parallel because both are critical elements. You need to ensure they are optimally functional and stable. Stability is key. The company is trying to instill an industrial mindset across the organization. Everyone will benefit by thinking of this as a product, not just fun work in the lab. Both upstream media and downstream resins are equally mission-critical.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

Thermo Fisher Scientific Inc: Culture and Management
Former Director at Thermo Fisher Scientific

Danaher, Aldevron, Intangible & Goodwill Impairments

Bruker and AI Applications in Mass Spectrometry
Former Director of Bruker

Porvair & Chromatography Lab Equipment: M&A Process & Culture
Former Senior Vice President Life Sciences at J.G. Finneran, Porvair plc
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.